Clinical Trials Logo

Clinical Trial Summary

Notwithstanding the continuous progress in cancer treatment, patients with cancer still have to cope with quality of life (QoL) - impairing complications. Especially an extensive spectrum of dermatologic toxicities has been associated with cancer treatments. The number and type of cutaneous toxicities have evolved over the past 50 years, paralleling the development of new chemotherapeutic agents. The chemotherapy-related skin toxicities can significantly impede the patient's emotional, physical, social, and financial well-being resulting in a poor QoL. In rare cases of severe cutaneous reactions, treatment modifications are needed, resulting in a diminished overall survival. Important organizations in the field of oncology and supportive care, such as the MASCC, the ASCO, and the ESMO, have developed guidelines for the management of cancer therapy- related cutaneous toxicities based on available scientific evidence. Still, for some interventions, the evidence of recommendation is moderate to insufficient. Therefore, it is essential to elucidate other new potential management strategies for dermatological complications of cancer treatment. Based on the previously mentioned supportive care guidelines for the ChemoSkin project, a novel emollient to tackle the cutaneous adverse events of chemotherapy has been developed. The ChemoSkin project general aim is to evaluate the efficacy of a novel skincare product to manage chemotherapy-related cutaneous toxicities.


Clinical Trial Description

Primary objective Evaluate the efficacy of a novel emollient for the management of chemotherapy-related cutaneous adverse events Secondary objective 1 Evaluate patient-relevant treatment benefit of the novel emollient for chemotherapy-associated cutaneous toxicities Secondary objective 2 Evaluate the influence of the novel emollient for chemotherapy- associated cutaneous toxicities on the patient's quality of life Secondary objective 3 Evaluate the safety of the novel emollient for chemotherapy- associated cutaneous toxicities ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04929847
Study type Interventional
Source Jessa Hospital
Contact
Status Completed
Phase N/A
Start date October 20, 2021
Completion date September 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04929834 - Novel Skin Care for Immunotherapy- Related Dermatologic Toxicities N/A
Not yet recruiting NCT03606954 - Potency of Topical Corticosteroids in Combination Preparations Phase 4
Completed NCT01976481 - Serum 25-OH Vitamin D Modulation by Sunbed Use According to EU Guideline EN 60335-2-27 N/A
Completed NCT03448731 - Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA) Phase 2
Recruiting NCT05109858 - Skin Toxicity by Oncological Therapies
Completed NCT00871429 - Skin Care for Cancer Patients: A Product Satisfaction Survey N/A
Recruiting NCT04469075 - Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields Phase 2
Recruiting NCT04650256 - Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences N/A
Terminated NCT01317433 - Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer N/A
Active, not recruiting NCT03167268 - Panitumumab Skin Toxicity Prevention Trial Phase 2
Recruiting NCT06118047 - Crisaborole Ointment for Skin Toxicity Induced by Cetuximab Phase 2